



## **Cancer vaccine firm Oxford Vacmedix closes \$12.5m Series A funding**

*South Korean and Chinese investors join round into Oxford University spinout developing cancer vaccines.*

**Oxford, UK - 6th March 2018 – FOR IMMEDIATE RELEASE**

Oxford Vacmedix UK Limited (OVM), a UK-based biopharma company focused on the development of cancer vaccines, has completed its Series A financing round of \$12.5m (£9m) with a consortium of South Korean and Chinese investors.

OVM will use the funds to complete preclinical development and to enter Phase 1 clinical trials with its two lead vaccines, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines will be developed as single agents and in combination with immune-oncology agents. The company will also continue to develop its diagnostic kits for cellular immunity.

Spun out by Oxford University Innovation in 2012, OVM is commercialising research led by Dr Shisong Jiang, developed as a partnership between Oxford University's Department of Oncology and the Medical Research Council's Weatherall Institute of Molecular Medicine, also based in Oxford. The technology uses the novel, proprietary platform of recombinant overlapping peptides to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy.

OVM secured Series A investment from Cancer ROP, a leading South Korean healthcare institution, listed in KOSDAQ, and from existing shareholders in China. The financing round represents the first time that a UK cancer vaccines company has been financed by both South Korean and Chinese investors.

William Finch, CEO and Director at OVM, said:

"We are delighted to have such an experienced group of international investors support the company in this financing round. This investment will allow OVM's cancer vaccines to be progressed to important clinical milestones both to benefit patients and to return significant shareholder value. We have already licensed our technology into Chinese market and we are also looking forward to collaborating with Cancer ROP on the development of our vaccines in the Republic of Korea".

Shisong Jiang, Founder and Chief Scientific Officer at OVM, added:

"This Series A investment will allow us to further develop ROP technology – a quick and economic way to produce vaccines and diagnostics for cancer and infectious diseases. We hope our effort will eventually benefit the health of many patients."

### **Oxford University Innovation**

Buxton Court, 3 West Way, Botley, Oxford OX2 0JB

T +44 (0)1865 280830 E [enquiries@innovation.ox.ac.uk](mailto:enquiries@innovation.ox.ac.uk) [www.innovation.ox.ac.uk](http://www.innovation.ox.ac.uk)

Company No 2199542 Registered Office: University Offices, Wellington Square, Oxford OX1 2JD VAT No 490 7988 85





Wang-Jun Lee, Chairman at Cancer ROP, added:

“We look forward to a productive and mutually beneficial partnership with OVM especially in global clinical trial aspects and confident that we can support the continued growth and development of the company.”

**ENDS**

For more information or to arrange an interview, please contact:

Gregg Bayes-Brown, Marketing and Communications Manager, Oxford University Innovation

T: +44 (0)1865 280867 | E: [gregg.bayes-brown@innovation.ox.ac.uk](mailto:gregg.bayes-brown@innovation.ox.ac.uk)

**Notes to Editor**

**About Oxford Vacmedix**

Oxford Vacmedix UK Ltd, based on the Oxford Science Park, UK, is a bio-pharma company that utilizes the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for cancer therapeutic vaccines and diagnostics. The company is a spin-out of the University of Oxford and has extensive contacts and collaborations in China through Changzhou Bioscience that is using the ROP platform in both diagnostics and adoptive cell therapy.

For more information, please visit: <http://www.oxfordvacmedix.com/>

**About Cancer ROP Co., Ltd.**

Cancer ROP is a molecular diagnostics company in Korea, focused on genetic diagnosis. Cancer ROP's genetic diagnosis is aimed at detecting genetic diseases occurring at all stages of human life. Cancer ROP has exclusively produced microarray (BAC DNA Chip) based on the genes obtained from the Korean Genome Projects and has launched NGS service using own clinical database. Cancer ROP was established in 2001 and was acquired by Myongji Hospital-led investment association in 2017.

**About Oxford University Innovation**

Oxford University Innovation supports innovation activities across all University Divisions, managing technology transfer and consulting activities, and creating a world-leading innovation ecosystem, with Oxford University at its heart.



We provide access to technology from Oxford researchers through intellectual property licensing, spinout company formation and material sales, and to academic expertise through our Consulting Services team. The New Venture Support & Funding team supports investors or donors with an interest in early-stage ventures, and manages the Oxford Angels Network.

Our Start-up Incubator supports members and ex-members of the University who wish to start or grow entrepreneur-driven ventures that are not University spinouts.

Oxford University Innovation is the highest university patent filer in the UK and is ranked 1st in the UK for university spinouts, having created over 170 new companies since 1988. In the 2016/17 financial year we completed more than 50 licenses and consulting agreements every month. For updates on innovations from Oxford, follow Oxford University Innovation on [LinkedIn](#) and [Twitter](#) or subscribe at <http://innovation.ox.ac.uk/about/contact-us/#enquiry>